| ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA a Jiří MAYER. Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF). In 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021. 2021. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1830779,
author = {Žáčková, Daniela and Faber, Edgar and Stejskal, L. and Karas, M. and Bělohlávková, P. and Klamová, H. and Černá, O. and Cmunt, Eduard and Čičátková, Petra and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Wiewiorka, Ondřej and Mayer, Jiří},
booktitle = {23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021},
keywords = {tyrosine kinase inhibitors; chronic myeloid leukemia},
language = {eng},
title = {Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).},
year = {2021}
}
TY - CONF
ID - 1830779
AU - Žáčková, Daniela - Faber, Edgar - Stejskal, L. - Karas, M. - Bělohlávková, P. - Klamová, H. - Černá, O. - Cmunt, Eduard - Čičátková, Petra - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Wiewiorka, Ondřej - Mayer, Jiří
PY - 2021
TI - Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).
KW - tyrosine kinase inhibitors
KW - chronic myeloid leukemia
N2 - Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF) - conference abstract from 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021.
ER -
ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA a Jiří MAYER. Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF). In \textit{23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021}. 2021.
|
